BRPI0410739A - composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa) - Google Patents
composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa)Info
- Publication number
- BRPI0410739A BRPI0410739A BRPI0410739-0A BRPI0410739A BRPI0410739A BR PI0410739 A BRPI0410739 A BR PI0410739A BR PI0410739 A BRPI0410739 A BR PI0410739A BR PI0410739 A BRPI0410739 A BR PI0410739A
- Authority
- BR
- Brazil
- Prior art keywords
- tumor necrosis
- receptor antagonist
- pharmaceutical composition
- necrosis factor
- alpha
- Prior art date
Links
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title abstract 3
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003390 tumor necrosis factor Human genes 0.000 title 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- YNZTXTGFUQRXMU-UHFFFAOYSA-N [2-(1-adamantylamino)-2-oxo-1-phenylethyl] propanoate Chemical compound C1C(C2)CC(C3)CC2CC13NC(=O)C(OC(=O)CC)C1=CC=CC=C1 YNZTXTGFUQRXMU-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0312321A GB0312321D0 (en) | 2003-05-29 | 2003-05-29 | New combination |
| SE0301655A SE0301655D0 (sv) | 2003-06-05 | 2003-06-05 | New combination |
| PCT/SE2004/000817 WO2004105798A1 (en) | 2003-05-29 | 2004-05-27 | A PHARMACEUTICAL COMPOSITION COMPRISING A P2X7-RECEPTOR ANTAGONIST AND A TUMOUR NECROSIS FACTOR α |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0410739A true BRPI0410739A (pt) | 2006-06-27 |
Family
ID=33492248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0410739-0A BRPI0410739A (pt) | 2003-05-29 | 2004-05-27 | composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070032465A1 (https=) |
| EP (1) | EP1633401A1 (https=) |
| JP (1) | JP2007501270A (https=) |
| KR (1) | KR20060037258A (https=) |
| AR (1) | AR044452A1 (https=) |
| BR (1) | BRPI0410739A (https=) |
| CA (1) | CA2526883A1 (https=) |
| CO (1) | CO5640094A2 (https=) |
| IS (1) | IS8188A (https=) |
| MX (1) | MXPA05012705A (https=) |
| NO (1) | NO20056131L (https=) |
| RU (1) | RU2350354C2 (https=) |
| TW (1) | TW200507829A (https=) |
| UY (1) | UY28335A1 (https=) |
| WO (1) | WO2004105798A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
| SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
| SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
| WO2006095355A1 (en) * | 2005-03-07 | 2006-09-14 | Ganga Raju Gokaraju | Novel salts of boswellic acids and selectively enriched boswellic acids and processes for the same |
| GB0919594D0 (en) | 2009-11-09 | 2009-12-23 | Glaxo Group Ltd | Compounds |
| JP2013521002A (ja) | 2010-03-05 | 2013-06-10 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 誘導樹状細胞組成物及びその使用 |
| US9538710B2 (en) | 2010-04-01 | 2017-01-10 | Tony Wayne Covely | Crop product tracking system and method |
| US10444122B2 (en) | 2010-04-01 | 2019-10-15 | Agri-Labs Holdings Llc | Soil sample tracking system and method |
| CN103841969A (zh) * | 2011-08-04 | 2014-06-04 | 美国卫生和人力服务部 | 经由药物介导的对类二十烷酸平衡的操作治疗和预防微生物介导的疾病 |
| NZ701915A (en) | 2012-05-18 | 2016-11-25 | Genentech Inc | High-concentration monoclonal antibody formulations |
| KR102035463B1 (ko) * | 2018-02-14 | 2019-11-26 | 연세대학교 산학협력단 | 암 줄기세포의 치료용 약학 조성물 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3471491A (en) * | 1967-08-28 | 1969-10-07 | Squibb & Sons Inc | Adamantyl-s-triazines |
| US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
| US4349552A (en) * | 1978-10-30 | 1982-09-14 | Fujisawa Pharmaceutical Company, Ltd. | 5-Fluorouracil derivatives, and their pharmaceutical compositions |
| US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
| US5399564A (en) * | 1991-09-03 | 1995-03-21 | Dowelanco | N-(4-pyridyl or 4-quinolinyl) arylacetamide and 4-(aralkoxy or aralkylamino) pyridine pesticides |
| EP0952832B1 (en) * | 1996-05-20 | 2008-08-27 | Darwin Discovery Limited | Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors |
| SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| CN1147483C (zh) * | 1999-04-09 | 2004-04-28 | 阿斯特拉曾尼卡有限公司 | 金刚烷衍生物 |
| SE9904505D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
| TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
| GB0013737D0 (en) * | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| US8058441B2 (en) * | 2001-07-02 | 2011-11-15 | N.V. Organon | Tetrahydroquinoline derivatives |
| WO2003042190A1 (en) * | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
| PA8557501A1 (es) * | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| SE0103836D0 (sv) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| US6908939B2 (en) * | 2001-12-21 | 2005-06-21 | Galderma Research & Development S.N.C. | Biaromatic ligand activators of PPARγ receptors |
| SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
| SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
| SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| EP1644042A1 (en) * | 2003-05-29 | 2006-04-12 | AstraZeneca AB | A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| WO2004105797A1 (en) * | 2003-05-29 | 2004-12-09 | Astrazeneca Ab | A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
| SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
-
2004
- 2004-05-27 TW TW093115142A patent/TW200507829A/zh unknown
- 2004-05-27 WO PCT/SE2004/000817 patent/WO2004105798A1/en not_active Ceased
- 2004-05-27 MX MXPA05012705A patent/MXPA05012705A/es not_active Application Discontinuation
- 2004-05-27 US US10/558,354 patent/US20070032465A1/en not_active Abandoned
- 2004-05-27 JP JP2006532213A patent/JP2007501270A/ja active Pending
- 2004-05-27 KR KR1020057022669A patent/KR20060037258A/ko not_active Ceased
- 2004-05-27 RU RU2005136131/15A patent/RU2350354C2/ru not_active IP Right Cessation
- 2004-05-27 BR BRPI0410739-0A patent/BRPI0410739A/pt not_active IP Right Cessation
- 2004-05-27 EP EP04735147A patent/EP1633401A1/en not_active Withdrawn
- 2004-05-27 CA CA002526883A patent/CA2526883A1/en not_active Abandoned
- 2004-05-28 AR ARP040101848A patent/AR044452A1/es unknown
- 2004-05-28 UY UY28335A patent/UY28335A1/es unknown
-
2005
- 2005-11-24 CO CO05119402A patent/CO5640094A2/es not_active Application Discontinuation
- 2005-12-20 IS IS8188A patent/IS8188A/is unknown
- 2005-12-22 NO NO20056131A patent/NO20056131L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20060037258A (ko) | 2006-05-03 |
| US20070032465A1 (en) | 2007-02-08 |
| CA2526883A1 (en) | 2004-12-09 |
| RU2005136131A (ru) | 2006-07-27 |
| CO5640094A2 (es) | 2006-05-31 |
| WO2004105798A1 (en) | 2004-12-09 |
| IS8188A (is) | 2005-12-20 |
| AU2004243137A1 (en) | 2004-12-09 |
| AR044452A1 (es) | 2005-09-14 |
| MXPA05012705A (es) | 2006-02-08 |
| RU2350354C2 (ru) | 2009-03-27 |
| JP2007501270A (ja) | 2007-01-25 |
| UY28335A1 (es) | 2004-12-31 |
| TW200507829A (en) | 2005-03-01 |
| EP1633401A1 (en) | 2006-03-15 |
| NO20056131L (no) | 2006-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0410739A (pt) | composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa) | |
| BRPI0410933A (pt) | novos antagonistas do receptor p2x7 e seu uso | |
| BR112022004986A2 (pt) | Anticorpos anti-tnfr2 e métodos de uso | |
| BRPI0414558A (pt) | composição farmacêutica compreendendo um antagonista do receptor p2x7 e uma droga antiinflamatória não esteróide | |
| EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
| PA8601901A1 (es) | Pirazoles como inhibidores de factor de necrosis tumoral | |
| BRPI0013478B8 (pt) | medicamento compreendendo inibidor pde e uso de roflumilast | |
| BRPI0819703A2 (pt) | Uso de inibidores de proteína tirosina fosfatase e hormônio de crescimento humano, uso de igf1 e um inibidor de proteína tirosina fosfatase e composição de combinação farmacêutica para o tratamento de atrofia muscular e distúrbios relacionados | |
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| ECSP034773A (es) | Pirazolopirimmidinas como agentes terapeuticos | |
| BRPI0409910A (pt) | métodos para o tratamento de doenças relacionadas com interleucina-6 | |
| NO20060128L (no) | Krystallinske tumornekrosesfaktor reseptor 2-polypeptider | |
| CL2009001936A1 (es) | Compuestos derivados de piridazina, inhibidores de 11beta-hsd1; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de la diabetes, obesidad, dislipidemia, trastornos de ingestion de comida e hipertension (divisional de solicitud 1720-2006). | |
| BRPI0316532B8 (pt) | composições farmacêuticas compreendendo uma droga básica ou ácida, um tensoativo, e um ácido ou base solúvel em água fisiologicamente tolerável | |
| BR0110028A (pt) | Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica | |
| ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
| BR0211274A (pt) | Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase | |
| CL2008000021A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer. | |
| TW200730168A (en) | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | |
| BRPI0410495A (pt) | composição para o tratamento de uma doença inflamatória dos intestinos e uso de um antagonista de interferon tipo i para preparar um medicamento | |
| BRPI0412919A (pt) | combinação de antagonista de mglur2 e inibidor de ache para o tratamento de distúrbios neurológicos crÈnicos e/ou agudos | |
| CY1109537T1 (el) | Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης | |
| ATE468341T1 (de) | Thienopyrazole | |
| ITRM20030363A1 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. | |
| BR0206819A (pt) | Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |